Cancer survival gaps persist: AACR report reveals racial, income disparities in US care

Progress in Mortality Rates Since 1991

The landscape of cancer treatment has seen substantial improvement over the last three decades. According to the AACR Cancer Disparities Progress Report 2026, the steady decline in cancer death rates has prevented more than 4.8 million deaths since 1991. This progress has contributed to a growing population of nearly 19 million cancer survivors.

Despite these gains, the report emphasizes that the benefits of research are not distributed equally. The gap in mortality rates between Black and White individuals has narrowed—falling from a 34% disparity in 1991 to 9% in 2024—yet Black and American Indian or Alaska Native populations still face higher overall cancer mortality rates than their White counterparts. This progress reflects advancements in screening technologies, such as low-dose computed tomography for lung cancer and colonoscopies for colorectal cancer, as well as the development of targeted therapies and immunotherapies. However, the report cautions that these clinical tools often reach marginalized populations later than the general public, if at all.

Social and Structural Drivers of Inequality

Medical outcomes are frequently tied to social drivers of health, including housing, education, and insurance status. The AACR report identifies a constellation of factors, such as systemic racism and geographic isolation, that prevent equitable access to care. For those living in persistent-poverty counties, the outlook is particularly grim; cervical cancer mortality rates in these areas are 49% higher than in non-poverty regions.

Geography also plays a definitive role in patient prognosis. Residents of rural counties are 17% more likely to be diagnosed with colorectal cancer and 27% more likely to die from the disease than those in metropolitan areas. These rural populations are also experiencing slower declines in their overall cancer mortality rates compared to urban residents. This disparity is often attributed to the limited availability of specialized oncology centers, a lack of transportation to urban academic medical centers, and a shortage of oncologists in rural settings, which forces patients to delay or forgo complex treatment regimens.

Disparities Across Specific Populations

The burden of disease varies significantly across different ethnic and demographic groups.

• Black individuals: Experience higher rates of multiple myeloma and prostate cancer.
• American Indian or Alaska Native individuals: Face higher rates of colorectal, kidney, and cervical cancers, alongside the largest increases in early-onset colorectal cancer.
• Hispanic and Asian populations: Show higher rates of infection-related cancers, such as stomach and liver cancer.
• Asian women: Data indicates a rising incidence of lung cancer among those who have never smoked, as reported by phillytrib.com.
• Lesbian women: Face a nearly twofold higher incidence of non-Hodgkin lymphoma and thyroid cancer compared to heterosexual women.

These findings underscore that cancer is not a monolithic disease. Variations in genetic predisposition, combined with differential exposures to environmental carcinogens and varying access to preventative screenings, create unique risk profiles for different segments of the U.S. population.

Bridging the Gap in Clinical Care

Experts argue that technological and clinical advancements are only effective if they are accessible to the entire population. The report underscores that a person’s zip code, insurance coverage, and ability to participate in clinical trials remain major barriers to survival. Clinical trials, which often provide access to cutting-edge experimental treatments, frequently suffer from a lack of demographic diversity. This underrepresentation can lead to a limited understanding of how new therapies affect diverse populations, potentially hindering the development of personalized treatment plans.

“The full impact of research progress can only be realized when it reaches all the people who need it. Cancer touches every community, yet, sadly, the burden is not shared equally. A person’s race, ethnicity, income, zip code, insurance status, access to screening [and], the ability to enroll in a clinical trial in the proximity to overall high-quality cancer care shape whether cancer is found early, treated effectively, and ultimately cured. This is why this report is so vitally important.”

Margaret Foti, Chief Executive Officer of AACR

As the medical community moves through 2026, the focus remains on addressing these multifactorial drivers. With all racial and ethnic minority individuals currently reporting lower 5-year relative survival rates than White individuals, the challenge for the coming years lies in translating scientific breakthroughs into tangible, equitable care for every community. Readers should understand that while population-level data identifies these trends, individual health outcomes are complex and influenced by personal history. Patients concerned about these disparities or their own risk factors should consult their healthcare provider to discuss personalized screening schedules and access to specialized care.

Find more reporting in our Health section.